



Summary of Studies Supporting USDA Product Licensure

Establishment Name	Boehringer Ingelheim Animal Health USA Inc.
USDA Vet Biologics Establishment Number	124
Product Code	1505.23
True Name	Equine Influenza Vaccine, Killed Virus
Tradename(s) / Distributor or Subsidiary (if different from manufacturer)	Vetera EIVxp - No distributor specified
Date of Compilation Summary	November 27, 2020

Disclaimer: Do not use the following studies to compare one product to another. Slight differences in study design and execution can render the comparisons meaningless.


Study Type	Efficacy
Pertaining to	Equine influenza virus
Study Purpose	Demonstration of 6-month duration of immunity against respiratory disease caused by equine influenza
Product Administration	Two doses, administered intramuscularly, 21 days apart. Vaccinates received test product, and controls received adjuvanted diluent.
Study Animals	30 horses (20 vaccinates, 10 controls), 5-6 months of age
Challenge Description	Influenza A/eq/Ohio/2003 administered 184 days post-final vaccination
Interval observed after challenge	Horses were observed daily for 10 days post-challenge
Results	<p>See tables at the end of document for data.</p> <p>Clinical Signs: An animal was considered positive (affected by challenge) if the animal exhibited:</p> <ul style="list-style-type: none"> • Fever (temperature >102.5°F), OR • Nasal discharge (moderate serous discharge or mucopurulent discharge), OR • Ocular discharge <p>A total of 9/10 (90%) controls were positive as compared to only 9/20 (45%) vaccinates.</p> <p>There were no adverse reactions to vaccine administration at any timepoint.</p>
USDA Approval Date	September 7, 2010

Treatment	Clinical Sign	Days Post-challenge										
		0	1	2	3	4	5	6	7	8	9	10
Controls												
1	Fever											
	Nasal discharge							+	+	+	+	
	Ocular discharge							+			+	+
2	Fever											
	Nasal discharge			+				+		+	+	
	Ocular discharge							+	+			+
3	Fever											
	Nasal discharge								+		+	
	Ocular discharge			+				+			+	+
4	Fever											
	Nasal discharge											
	Ocular discharge							+	+	+		+
5	Fever											
	Nasal discharge						+	+	+	+	+	
	Ocular discharge											
6	Fever											
	Nasal discharge						+			+		+
	Ocular discharge											+
7	Fever											
	Nasal discharge			+				+		+		+
	Ocular discharge			+					+			
8	Fever									+		
	Nasal discharge							+	+	+		+
	Ocular discharge			+	+			+	+			+
9	Fever											
	Nasal discharge											
	Ocular discharge											
10	Fever											
	Nasal discharge							+	+	+	+	+
	Ocular discharge						+	+		+	+	+

Treatment	Clinical Sign	Days Post-challenge												
		0	1	2	3	4	5	6	7	8	9	10		
Vaccinates														
1	Fever													
	Nasal discharge													
	Ocular discharge													
2	Fever													
	Nasal discharge													
	Ocular discharge													
3	Fever													
	Nasal discharge													
	Ocular discharge							+			+	+		
4	Fever													
	Nasal discharge									+				
	Ocular discharge													
5	Fever													
	Nasal discharge													
	Ocular discharge													
6	Fever													
	Nasal discharge													
	Ocular discharge													
7	Fever													
	Nasal discharge													
	Ocular discharge													
8	Fever													
	Nasal discharge													
	Ocular discharge													
9	Fever													
	Nasal discharge													
	Ocular discharge													
10	Fever							+						
	Nasal discharge								+	+				
	Ocular discharge										+		+	
11	Fever													
	Nasal discharge							+			+	+	+	
	Ocular discharge													
12	Fever													
	Nasal discharge										+			
	Ocular discharge													


Treatment	Clinical Sign	Days Post-challenge											
		0	1	2	3	4	5	6	7	8	9	10	
Vaccinates													
13	Fever												
	Nasal discharge						+						+
	Ocular discharge												
14	Fever												
	Nasal discharge												
	Ocular discharge												
15	Fever												
	Nasal discharge												
	Ocular discharge							+		+			
16	Fever												
	Nasal discharge								+				
	Ocular discharge												
17	Fever												
	Nasal discharge												
	Ocular discharge												
18	Fever												
	Nasal discharge												
	Ocular discharge												
19	Fever												
	Nasal discharge								+		+		
	Ocular discharge												
20	Fever												
	Nasal discharge												
	Ocular discharge												

Study Type	Efficacy
Pertaining to	Equine influenza virus
Study Purpose	Demonstration of efficacy against respiratory disease and shedding caused by equine influenza
Product Administration	Two doses, administered intramuscularly, 21 days apart.
Study Animals	37 horses (18 vaccinates, 19 controls), approximately 9-10 months of age
Challenge Description	Influenza A/eq/Ohio/2003 administered 3 weeks post-final vaccination
Interval observed after challenge	Horses were observed, and nasal swabs were collected, daily for 15 days post-challenge.
Results	<p>See tables at the end of document for data.</p> <p>Clinical Signs: An animal was considered positive (affected by challenge) if the animal exhibited the following at any post-challenge observation point:</p> <ul style="list-style-type: none"> • Fever (temperature $\geq 102.5^{\circ}\text{F}$), OR • Ocular discharge, OR • Nasal discharge (very slight mucopurulent discharge, or worse) <p>Duration of disease was calculated from the date the animal was first observed to be positive to the date of last positive observation for that animal. Based on this calculation, the median duration of disease for the controls was determined to be 11 days as compared to 3 days for the vaccinates.</p> <p>Nasal shedding of influenza virus was evaluated through nasal swab virus isolation results. An animal was considered positive if virus was isolated from nasal swabs on one or more occasions following challenge.</p> <p>0/18 vaccinates shed virus and 12/19 controls shed virus.</p> <p>There were no adverse reactions to vaccine administration at any timepoint.</p>
USDA Approval Date	April 8, 2013



Ocular Discharge: 0=none; 1=mild to moderate; 2=severe

Nasal Discharge: 0=none; 1=slight clear serous, as may be observed in both normal and diseased horses; 1.5=very slight mucopurulent discharge, one or both nostrils; 2=moderate clear serous discharge, easily seen in one or both nostrils; 3=Abundant clear serous discharge typically seen only in diseased horses; 4=moderately mucopurulent, in large quantities in both nostrils; 5=heavy mucopurulent discharge in large amounts in both nostrils



Ocular Discharge: 0=none; 1=mild to moderate; 2=severe

Nasal Discharge: 0=none; 1=slight clear serous, as may be observed in both normal and diseased horses; 1.5=very slight mucopurulent discharge, one or both nostrils; 2=moderate clear serous discharge, easily seen in one or both nostrils; 3=Abundant clear serous discharge typically seen only in diseased horses; 4=moderately mucopurulent, in large quantities in both nostrils; 5=heavy mucopurulent discharge in large amounts in both nostrils

Study Type	Efficacy
Pertaining to	Equine influenza
Study Purpose	Demonstration of efficacy against respiratory disease caused by equine influenza A2 strain Richmond 07
Product Administration	Two doses, administered intramuscularly, 21 days apart
Study Animals	20 horses (20 vaccinates), 12 months of age
Challenge Description	Not applicable
Interval observed after challenge	Not applicable
Results	This product class allows the manufacturer to update micro-organisms in this vaccine under expedited procedures to respond to emerging needs. Abbreviated data to support influenza strain updates to the product composition were evaluated by USDA-APHIS and found to be acceptable based on regulations and policies at the time of approval. Full vaccination-challenge studies may not have been required for these updates.
USDA Approval Date	February 2, 2012

Study Type	Efficacy
Pertaining to	Equine influenza
Study Purpose	Demonstration of efficacy against respiratory disease caused by equine influenza A2 strain Kentucky 95
Product Administration	Two doses, administered intramuscularly, 21 days apart
Study Animals	20 horses (20 vaccinates), 12 months of age
Challenge Description	Not applicable
Interval observed after challenge	Not applicable
Results	This product class allows the manufacturer to update micro-organisms in this vaccine under expedited procedures to respond to emerging needs. Abbreviated data to support influenza strain updates to the product composition were evaluated by USDA-APHIS and found to be acceptable based on regulations and policies at the time of approval. Full vaccination-challenge studies may not have been required for these updates.
USDA Approval Date	February 2, 2012

Study Type	Safety																																																																																																																																											
Pertaining to	All fractions																																																																																																																																											
Study Purpose	To demonstrate safety under field conditions at three different test sites																																																																																																																																											
Product Administration	2 doses given intramuscularly 21 days apart																																																																																																																																											
Study Animals	622 horses vaccinated with two doses including: <ul style="list-style-type: none"> • 203-two to four month-old foals • 19-five to seven month-old foals • 400-1 year or older horses 																																																																																																																																											
Challenge Description	Not Applicable																																																																																																																																											
Interval observed after vaccination	Horses were observed on Days 0, 1 and 3 following the first vaccination and on Days 1, 3 and 7 following the second vaccination for systemic and local injection site reactions.																																																																																																																																											
Results	<p>There were no systemic reactions observed at any of the three sites. Local injection site reactions are summarized below.</p> <p>North Dakota Site:</p> <table border="1"> <thead> <tr> <th rowspan="2">Summary</th> <th rowspan="2">Total Number</th> <th rowspan="2">Number with 2 doses</th> <th colspan="2">Transient Injection Site Swelling</th> <th colspan="2">Number Normal</th> </tr> <tr> <th>1st dose</th> <th>2nd dose</th> <th>1st dose</th> <th>2nd dose</th> </tr> </thead> <tbody> <tr> <td>Age</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> </tr> <tr> <td>2-4 mo</td> <td>149</td> <td>149</td> <td>0</td> <td>0</td> <td>149</td> <td>149</td> </tr> <tr> <td>5-7 mo</td> <td>0</td> <td>0</td> <td>n/a</td> <td>n/a</td> <td>n/a</td> <td>n/a</td> </tr> <tr> <td>8-11 mo</td> <td>0</td> <td>0</td> <td>n/a</td> <td>n/a</td> <td>n/a</td> <td>n/a</td> </tr> <tr> <td>1 yr-5yr</td> <td>23</td> <td>23</td> <td>0</td> <td>0</td> <td>23</td> <td>23</td> </tr> <tr> <td>6-15 yr</td> <td>121</td> <td>121</td> <td>0</td> <td>0</td> <td>121</td> <td>121</td> </tr> <tr> <td>>16 yr</td> <td>3</td> <td>3</td> <td>0</td> <td>0</td> <td>3</td> <td>3</td> </tr> <tr> <td>Total</td> <td>296</td> <td>296</td> <td>0</td> <td>0</td> <td>296</td> <td>296</td> </tr> </tbody> </table> <p>California Site:</p> <table border="1"> <thead> <tr> <th rowspan="2">Summary</th> <th rowspan="2">Total Number</th> <th rowspan="2">Number with 2 doses</th> <th colspan="2">Transient Injection Site Swelling</th> <th colspan="2">Number Normal</th> </tr> <tr> <th>1st dose</th> <th>2nd dose</th> <th>1st dose</th> <th>2nd dose</th> </tr> </thead> <tbody> <tr> <td>Age</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> </tr> <tr> <td>2-4 mo</td> <td>0</td> <td>0</td> <td>n/a</td> <td>n/a</td> <td>n/a</td> <td>n/a</td> </tr> <tr> <td>5-7 mo</td> <td>5</td> <td>5</td> <td>0</td> <td>0</td> <td>5</td> <td>5</td> </tr> <tr> <td>8-11 mo</td> <td>0</td> <td>0</td> <td>n/a</td> <td>n/a</td> <td>n/a</td> <td>n/a</td> </tr> <tr> <td>1 yr-5yr</td> <td>25</td> <td>25</td> <td>0</td> <td>4</td> <td>25</td> <td>21</td> </tr> <tr> <td>6-15 yr</td> <td>15</td> <td>15</td> <td>0</td> <td>3</td> <td>15</td> <td>12</td> </tr> <tr> <td>>16 yr</td> <td>6</td> <td>6</td> <td>0</td> <td>1</td> <td>6</td> <td>5</td> </tr> <tr> <td>Total</td> <td>51</td> <td>51</td> <td>0</td> <td>8*</td> <td>51</td> <td>43</td> </tr> </tbody> </table> <p>*Postvaccination reactions were minimal. The reported reactions were mild, transient, non-painful injection swellings.</p>						Summary	Total Number	Number with 2 doses	Transient Injection Site Swelling		Number Normal		1 st dose	2 nd dose	1 st dose	2 nd dose	Age							2-4 mo	149	149	0	0	149	149	5-7 mo	0	0	n/a	n/a	n/a	n/a	8-11 mo	0	0	n/a	n/a	n/a	n/a	1 yr-5yr	23	23	0	0	23	23	6-15 yr	121	121	0	0	121	121	>16 yr	3	3	0	0	3	3	Total	296	296	0	0	296	296	Summary	Total Number	Number with 2 doses	Transient Injection Site Swelling		Number Normal		1 st dose	2 nd dose	1 st dose	2 nd dose	Age							2-4 mo	0	0	n/a	n/a	n/a	n/a	5-7 mo	5	5	0	0	5	5	8-11 mo	0	0	n/a	n/a	n/a	n/a	1 yr-5yr	25	25	0	4	25	21	6-15 yr	15	15	0	3	15	12	>16 yr	6	6	0	1	6	5	Total	51	51	0	8*	51	43
Summary	Total Number	Number with 2 doses	Transient Injection Site Swelling		Number Normal																																																																																																																																							
			1 st dose	2 nd dose	1 st dose	2 nd dose																																																																																																																																						
Age																																																																																																																																												
2-4 mo	149	149	0	0	149	149																																																																																																																																						
5-7 mo	0	0	n/a	n/a	n/a	n/a																																																																																																																																						
8-11 mo	0	0	n/a	n/a	n/a	n/a																																																																																																																																						
1 yr-5yr	23	23	0	0	23	23																																																																																																																																						
6-15 yr	121	121	0	0	121	121																																																																																																																																						
>16 yr	3	3	0	0	3	3																																																																																																																																						
Total	296	296	0	0	296	296																																																																																																																																						
Summary	Total Number	Number with 2 doses	Transient Injection Site Swelling		Number Normal																																																																																																																																							
			1 st dose	2 nd dose	1 st dose	2 nd dose																																																																																																																																						
Age																																																																																																																																												
2-4 mo	0	0	n/a	n/a	n/a	n/a																																																																																																																																						
5-7 mo	5	5	0	0	5	5																																																																																																																																						
8-11 mo	0	0	n/a	n/a	n/a	n/a																																																																																																																																						
1 yr-5yr	25	25	0	4	25	21																																																																																																																																						
6-15 yr	15	15	0	3	15	12																																																																																																																																						
>16 yr	6	6	0	1	6	5																																																																																																																																						
Total	51	51	0	8*	51	43																																																																																																																																						

USDA Approval Date	Missouri Site:						
	Summary	Total Number	Number with 2 doses	Transient Injection Site Swelling		Number Normal	
	Age			1 st dose	2 nd dose	1 st dose	2 nd dose
	2-4 mo	55	54	0	0	55	54
	5-7 mo	15	14	0	0	15	14
	8-11 mo	0	0	n/a	n/a	n/a	n/a
	1 yr-5yr	134	132	0	0	134	132
	6-15 yr	68	68	0	0	68	68
	>16 yr	7	7	0	0	7	7
	Total	279	275	0	0	279	275
	Total Across Three Sites:						
	Site	Total Number	Number with 2 doses	Transient Injection Site Swelling		Number Normal	
				1 st dose	2 nd dose	1 st dose	2 nd dose
	North Dakota	296	296	0	0	296	296
	California	51	51	0	8*	51	43
Missouri	279	275	0	0	279	275	
Total	626	622	0	8*	626	614	
*Postvaccination reactions were minimal and described as mild, transient, non-painful swellings after the second vaccination in eight (8) older, heavily vaccinated horses. There were no systemic reactions observed.							
February 14, 2012							

Study Type	Safety
Pertaining to	All fractions
Study Purpose	To demonstrate safety in pregnant mares under field conditions at two different test sites
Product Administration	Two intramuscular doses, given 16-28 days apart. 54 pregnant mares were injected with placebo and 325 pregnant mares were vaccinated with test product.
Study Animals	Three hundred seventy-nine pregnant mares at two locations were included in the study. The mares were confirmed to be pregnant by serum hormonal evaluation on the day of the first vaccination.
Challenge Description	Not applicable
Interval observed after vaccination	1 st and 2 nd trimester: Mares observed immediately after vaccination and daily for overall health and for abortion. Resulting foals were observed daily for 7 days following birth. 3 rd trimester: Mares observed immediately after vaccination and daily for overall health and for abortion. Resulting foals were observed daily for 30 days following birth.
Results	Results shown on next page

Results**Study 2013-PM-1009****North Dakota Site:**

Group	Vaccinated	Confirmed Pregnant	Foals	Parturition Rate
1 st trimester/ product	143	127	114	90%
1st trimester/ placebo	59	54	49	91%
2 nd trimester/ product	6	6	6	100%
3 rd trimester/ product	140	117	117	100%
Total – all animals	348	304	286	94%
Total – product only	289	250	237	95%
Total – placebo only	59	54	49	91%

Study 2013-PM-1009**Missouri Site:**

Group	Vaccinated	Confirmed Pregnant	Foals	Parturition Rate
2011 3 rd trimester	5	5	5	100%
2012 1 st trimester	1	1	1	100%
2012 2 nd trimester	53	43	39	91%
2012 3 rd trimester	26	26	25	96%
Total – product	85	75	70	93%

Study 2014-PM-1009**North Dakota Site:**

Group	Vaccinated	Confirmed Pregnant	Foaled	Parturition Rate	Foals Survived to End of Observation Period
2 nd trimester vaccinated	52	52	52	100%	51*
3 rd trimester vaccinated	69	69	67**	97.1%	67

*Lost foal affirmed by study cooperator to be due to causes other than vaccination.

**One mare died due to causes other than vaccination, as affirmed by study cooperator.

All other foals were normal and healthy

USDA Approval Date

September 12, 2014